Patents Represented by Attorney David H. Vance

Find this attorney in the Justia Lawyer Directory

  • Lactam metalloprotease inhibitors
    Patent number: 6620823
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 4-8 membered cyclic amide comprising 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: September 16, 2003
    Assignee: Bristol-Myers Squibb Pharme Company
    Inventors: Thomas P Maduskuie, Jingwu Duan, Stephen E Mercer
  • Lactam metalloprotease inhibitors
    Patent number: 6610731
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings ring B is a 4-8 membered cyclic amide containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: August 26, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jingwu Duan, Carl P. Decicco, Zelda R. Wasserman, Thomas P. Maduskuie, Jr.
  • Thrombin or factor Xa inhibitors
    Patent number: 6602871
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: August 5, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, John M. Fevig, Robert A. Galemmo, Qi Han, Irina C. Jacobson, Renhau Li, Donald J. P. Pinto, Ruth R. Wexler
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 6602895
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 5, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Heteroaryl-phenyl substituted factor Xa inhibitors
    Patent number: 6599926
    Abstract: The present application describes heteroaryl-phenyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: July 29, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Mimi L. Quan, Francis J. Woerner
  • Thrombin or factor Xa inhibitors
    Patent number: 6586418
    Abstract: This invention relates generally to heteroaryl-phenyl substituted compounds that are inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 1, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Mimi L Quan
  • Thiazoles as factor Xa inhibitors
    Patent number: 6569874
    Abstract: The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(═NH)NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: May 27, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Russell Pruitt, John Matthew Fevig, Mimi Lifen Quan, Donald Joseph Phillip Pinto
  • Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa
    Patent number: 6552042
    Abstract: The present application describes inhibitors of factor Xa of formula I: or pharmaceutically acceptable salt forms thereof, wherein W, W1, W2, and W3 may be N or C and J, Ja, and Jb combine to form a substituted carbocycle or heterocycle.
    Type: Grant
    Filed: January 29, 2001
    Date of Patent: April 22, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Qi Han, Celia Dominguez, Eugene C. Amparo, Jeongsook M. Park, Mimi L. Quan, Karen A. Rossi
  • Nitrogen containing heteroaromatics as factor Xa inhibitors
    Patent number: 6548512
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(═NH)NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald Joseph Phillip Pinto, James Russell Pruitt, Joseph Cacciola, John Matthew Fevig, Qi Han, Michael James Orwat, Mimi Lifen Quan, Karen Anita Rossi
  • Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors
    Patent number: 6548525
    Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert A. Galemmo, Jr., Lori L. Bostrom, Donald J. P. Pinto, Karen A. Rossi
  • Efficient ligand-mediated Ullmann coupling of anilines and azoles
    Patent number: 6541639
    Abstract: The present invention provides of method of preparing phenyl-substituted azoles. This method uses an efficient ligand-accelerated Ullmann coupling reaction of anilines with azoles. The coupling products are useful for preparing factor Xa inhibitors.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: April 1, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jiacheng Zhou, Pasquale N. Confalone, Hui-Yin Li, Philip Ma, Lynette M. Oh, Lucius T. Rossano, Charles G. Clark, Chris Teleha
  • N-(amidinophenyl)cyclourea analogs as factor Xa inhibitors
    Patent number: 6521614
    Abstract: The present application describes N-(amidinophenyl)cyclourea analogs of formula I: which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas Peter Maduskuie, Jr., Robert Anthony Galemmo, Jr., Celia Dominguez, Mimi Lifen Quan, Karen Anita Rossi, Petrus Fredericus Wilhelmus Stouten, Jung-Hui Sun, Brian Lloyd Wells
  • Heteroaryl-phenyl heterobicyclic factor Xa inhibitors
    Patent number: 6506771
    Abstract: The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: January 14, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Donald J. P. Pinto, Mimi L. Quan, Francis J. Woerner, Renhua Li
  • Thrombin or factor Xa inhibitors
    Patent number: 6500855
    Abstract: This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: December 31, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Patrick Y. S. Lam, Charles G. Clark, Renhau Li, Donald J. P. Pinto
  • &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6495565
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: December 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Jr., Matthew E. Voss
  • Lactam inhibitors of matrix metalloproteinases, TNF-&agr; and aggrecanase
    Patent number: 6495548
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 4-8 membered lactam containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: December 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Jingwu Duan
  • Synthesis of 1,3,5-trisubstituted pyrazoles
    Patent number: 6465656
    Abstract: A novel process for making 1,3,5-trisubstituted pyrazoles of the type shown below from appropriate phenyl hydrazines is described. These compounds are useful as factor Xa inhibitors.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: October 15, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jiacheng Zhou, Lynette May Oh, Pasquale N. Confalone, Hui-Yin Li, Philip Ma
  • Cyclic sulfonamide derivatives as metalloproteinase inhibitors
    Patent number: 6455522
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings ring B is a 4-8 membered cyclic sulfonamide containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Lihua Chen, Robert J. Cherney, Carl P. Decicco, Matthew E. Voss
  • Disubstituted pyrazolines and triazolines as factor Xa inhibitors
    Patent number: 6436985
    Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M1 and M2 maybe N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: August 20, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Donald J. P. Pinto
  • Nitrogen containing heterobicycles as factor Xa inhibitors
    Patent number: 6429205
    Abstract: This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: August 6, 2002
    Assignee: Bristol-Meyers Squibb Pharma Company
    Inventors: Irina C. Jacobson, Mimi L. Quan